Galectin Therapeutics Announces That Oral Treatment With Galectin-3 Inhibitor GR-MD-02 Is Efficacious In Preclinical Model Of Fatty Liver Disease With Fibrosis

NORCROSS, Ga., June 23, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that a preclinical study in a mouse model of NASH (non-alcoholic steatohepatitis, or fatty liver disease) demonstrated that oral administration of the Company's lead galectin-3 inhibitor, GR-MD-02, resulted in significant disease improvement.

Help employers find you! Check out all the jobs and post your resume.